





# The *Aedes aegypti* Domino Ortholog p400 Regulates Antiviral Exogenous Small Interfering RNA Pathway Activity and *ago-2* Expression

Melanie McFarlane,<sup>a</sup> Floriane Almire,<sup>a</sup> Joy Kean,<sup>a</sup> Claire L. Donald,<sup>a</sup> Alma McDonald,<sup>a</sup> Bryan Wee,<sup>c</sup> Mathilde Lauréti,<sup>a</sup>  
 Margus Varjak,<sup>a</sup> Sandra Terry,<sup>a</sup> Marie Vazeille,<sup>b</sup> Rommel J. Gestuevo,<sup>a,d</sup> Isabelle Dietrich,<sup>a\*</sup> Colin Loney,<sup>a</sup>  
 Anna-Bella Failloux,<sup>b</sup> Esther Schnettler,<sup>a\*</sup> Emilie Pondeville,<sup>a</sup> Alain Kohl<sup>a</sup>

<sup>a</sup>MRC-University of Glasgow Centre for Virus Research, Glasgow, Scotland

<sup>b</sup>Arboviruses and Insect Vectors Unit, Department of Virology, Institut Pasteur, Paris, France

<sup>c</sup>Usher Institute for Population Health Sciences & Informatics, University of Edinburgh, Edinburgh, United Kingdom

<sup>d</sup>Division of Biological Sciences, University of the Philippines Visayas, Miagao, Philippines

Melanie McFarlane and Floriane Almire contributed equally to this work. Author order was agreed between co-first authors. Emilie Pondeville and Alain Kohl are joint senior authors.

**ABSTRACT** Arboviruses are pathogens of humans and animals. A better understanding of the interactions between these pathogens and the arthropod vectors, such as mosquitoes, that transmit them is necessary to develop novel control measures. A major antiviral pathway in the mosquito vector is the exogenous small interfering RNA (exo-siRNA) pathway, which is induced by arbovirus-derived double-stranded RNA in infected cells. Although recent work has shown the key role played by Argonaute-2 (Ago-2) and Dicer-2 (Dcr-2) in this pathway, the regulatory mechanisms that govern these pathways have not been studied in mosquitoes. Here, we show that the Domino ortholog p400 has antiviral activity against the alphavirus Semliki Forest virus (*Togaviridae*) both in *Aedes aegypti*-derived cells and *in vivo*. Antiviral activity of p400 was also demonstrated against chikungunya virus (*Togaviridae*) and Bunyamwera virus (*Peribunyaviridae*) but not Zika virus (*Flaviviridae*). p400 was found to be expressed across mosquito tissues and regulated *ago-2* but not *dcr-2* transcript levels in *A. aegypti* mosquitoes. These findings provide novel insights into the regulation of an important aedine exo-siRNA pathway effector protein, Ago-2, by the Domino ortholog p400. They add functional insights to previous observations of this protein's antiviral and RNA interference regulatory activities in *Drosophila melanogaster*.

**IMPORTANCE** Female *Aedes aegypti* mosquitoes are vectors of human-infecting arthropod-borne viruses (arboviruses). In recent decades, the incidence of arthropod-borne viral infections has grown dramatically. Vector competence is influenced by many factors, including the mosquito's antiviral defenses. The exogenous small interfering RNA (siRNA) pathway is a major antiviral response restricting arboviruses in mosquitoes. While the roles of the effectors of this pathway, Argonaute-2 and Dicer-2 are well characterized, nothing is known about its regulation in mosquitoes. In this study, we demonstrate that *A. aegypti* p400, whose ortholog Domino in *Drosophila melanogaster* is a chromatin-remodeling ATPase member of the Tip60 complex, regulates siRNA pathway activity and controls *ago-2* expression levels. In addition, we found p400 to have antiviral activity against different arboviruses. Therefore, our study provides new insights into the regulation of the antiviral response in *A. aegypti* mosquitoes.

**KEYWORDS** RNA interference, *ago-2*, arbovirus, innate immunity, mosquito, p400

**Citation** McFarlane M, Almire F, Kean J, Donald CL, McDonald A, Wee B, Lauréti M, Varjak M, Terry S, Vazeille M, Gestuevo RJ, Dietrich I, Loney C, Failloux A-B, Schnettler E, Pondeville E, Kohl A. 2020. The *Aedes aegypti* Domino ortholog p400 regulates antiviral exogenous small interfering RNA pathway activity and *ago-2* expression. *mSphere* 5:e00081-20. <https://doi.org/10.1128/mSphere.00081-20>.

**Editor** Ana Fernandez-Sesma, Icahn School of Medicine at Mount Sinai

**Copyright** © 2020 McFarlane et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Emilie Pondeville, [emilie.pondeville@glasgow.ac.uk](mailto:emilie.pondeville@glasgow.ac.uk), or Alain Kohl, [alain.kohl@glasgow.ac.uk](mailto:alain.kohl@glasgow.ac.uk).

\* Present address: Isabelle Dietrich, The Pirbright Institute, Pirbright, Surrey, United Kingdom; Esther Schnettler, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg, Germany, and German Centre for Infection Research (DZIF), partner site Hamburg-Luebeck-Borstel-Riems, Germany.

**Received** 28 January 2020

**Accepted** 13 March 2020


**Published** 8 April 2020

Arthropod-borne viruses (arboviruses) are transmitted to susceptible mammalian hosts through the bite of infected arthropod vectors, such as mosquitoes. This group of viruses includes those of medical and veterinary importance, such as chikungunya virus (CHIKV) (*Alphavirus; Togaviridae*), dengue virus (DENV) (*Flavivirus; Flaviviridae*), Zika virus (ZIKV) (*Flavivirus; Flaviviridae*), and Rift Valley fever virus (RVFV) (recently reclassified into *Phlebovirus; Phenuiviridae*) (1–6). Given the medical and economic impacts of arboviruses, viral interactions with mosquitoes and the impact on transmission remain important areas of research. New strategies to interfere with arbovirus transmission involve genetically modified mosquitoes, including making mosquitoes more resistant to arboviruses, as well as *Wolbachia*-endosymbiont-based approaches (7–15). Arboviruses infect and replicate in both mammalian host and vector host cells; as a consequence, they are detected by both mammalian and arthropod immune systems. Compared to the wealth of knowledge on the mammalian antiviral immune response, the arthropod response is not well characterized, yet it could provide important targets for novel vector control measures. Research on this topic has established that the key player in the antiviral immune response in mosquito vectors is the exogenous small interfering RNA (exo-siRNA) pathway (8, 16–19). This pathway is activated by the recognition of long viral double-stranded RNA (dsRNA) by the endo-RNase Dicer-2 (Dcr-2). The effector protein Dcr-2 cleaves viral dsRNA into 21-nucleotide (nt) virus-derived siRNAs (vsiRNAs), which are then loaded into the RNA-induced silencing complex (RISC). One key protein within RISC, Argonaute-2 (Ago-2), binds the siRNA and is believed to unwind the siRNA duplex and use one of the strands as a guide to specifically recognize complementary RNAs, targeting these for degradation. In the case of viral RNAs (such as genomes, antigenomes, or mRNAs), this results in an inhibition of virus replication. The antiviral activity mediated by the exo-siRNA pathway of vector mosquitoes has been demonstrated through the silencing or elimination/absence of effector proteins (such as Ago-2 or Dcr-2), which results in an upregulation of arbovirus replication. It has been shown to be active against arboviruses of all major families or orders, alphaviruses (20–29), flaviviruses (30–34), and bunyaviruses (35–37).

Although the importance of the key exo-siRNA pathway components, such as Ago-2, has been established, the regulation of this antiviral response, such as effector protein expression, activity, and activation, remains poorly understood. Given its attractiveness as a target for immunity-based control strategies in vectors, it is important that all of the components, including regulatory mediators, of the exo-siRNA pathway are better understood. In this study, we sought to identify new components of the antiviral exo-siRNA pathway with the aim of understanding how the pathway functions and how it is regulated. We show that the *Aedes aegypti* Domino ortholog p400 is expressed at different levels across mosquito tissues and is an antiviral factor, since silencing of the gene enhanced replication of the mosquito-borne alphavirus Semliki Forest virus (SFV). We confirmed that p400 not only acts on SFV but also on the SFV-related alphavirus CHIKV, as well as Bunyamwera virus (BUNV), a member of the *Peribunyaviridae* family. However, p400 did not show antiviral activity against ZIKV. In addition, we have identified p400 as a regulator of the exo-siRNA pathway activity, possibly by controlling *ago-2* but not *dcr-2* transcript levels *in vivo*. Thus, our results hint that this protein may exert antiviral activity through regulating the exo-siRNA pathway, although other antiviral pathways potentially regulated by p400 cannot be excluded. These findings help to further understand the regulation of the antiviral exo-siRNA pathway.

## RESULTS

**p400 is expressed in female mosquitoes.** Previous studies have reported the role of Domino in the antiviral response in *Drosophila melanogaster* (38). We therefore wanted to determine if the *A. aegypti* Domino ortholog, p400, has a similar role in mosquitoes. To determine if p400 was expressed in tissues relevant to arbovirus-mosquito interactions, we first investigated the presence of *p400* transcripts across mosquito tissues. For this, individual tissues were dissected and hemocytes perfused from non-blood-fed (NBF) female mosquitoes. RNA was extracted and transcript levels




**FIG 1** Detection of *p400* transcripts in tissues of NBF *A. aegypti* females. Presence of *p400* transcripts was determined in hemocytes, salivary glands, digestive tracts, ovaries, and carcasses of NBF females by RT-qPCR using the  $2^{-\Delta\Delta CT}$  method and expression in hemocytes as the reference sample. Bars represent the fold change in gene expression from 3 independent biological replicates (pools of 25 digestive tracts or ovaries, pools of 60 salivary glands, and pools of perfused hemocytes from 70 females per replicate). Error bars show the minimum and maximum fold change.

analyzed by reverse transcription-quantitative PCR (RT-qPCR). As shown in Fig. 1, *p400* transcripts were detected in hemocytes and all tissues tested. The expression levels of *p400* varied across tissues, with low levels in salivary glands and high levels in ovaries.

The presence of p400 was also investigated by immunofluorescence. Consistent with our RT-qPCR results, p400 was detected in hemocytes and several sampled tissues (Fig. 2). p400 was expressed in all perfused hemocytes. It was restricted to the nucleus in prohemocytes (Fig. 2A), which are small and spherical cells, with a high nuclear/cytoplasmic ratio (39). It was expressed in the nucleus as well as in the cytoplasm of differentiated hemocytes or granulocytes (Fig. 2B and C), which are bigger cells with filopodia and a low nuclear/cytoplasmic ratio (39). In tissues, p400 was detected in the nucleus of cells in the digestive tract, such as in the crop (Fig. 2E to H), in the ovarian sheath surrounding the whole ovary and oviduct (Fig. 2J and M to P), and in the ovariole sheath surrounding each ovariole (Fig. 2K and L). In ovarioles, p400 was expressed in some of the somatic cells forming the epithelium surrounding the germarium and the primary previtellogenic follicle (Fig. 2K and L). In the germarium, p400 was also strongly expressed in the nucleus of differentiating germ cells of the developing cyst (which will give rise to the secondary follicle) as well as in the germ line stem cells and to a lesser extent in the cystoblast germ cells (Fig. 2K). We also found p400 in the tracheal cells surrounding various tissues (Fig. 2D and I to K).


**p400 is antiviral against SFV in *A. aegypti* females.** Yasunaga et al. previously reported that Domino has antiviral activity against West Nile virus (WNV) and vesicular stomatitis virus (VSV) in *Drosophila* DL1 cells (38). Therefore, we sought to determine if the Domino ortholog p400 has similar antiviral activity in *A. aegypti* females. For this, we assessed whether p400 could be silenced *in vivo* and determined the effect of this knockdown on viral infection using the model alphavirus SFV. Female *A. aegypti* mosquitoes were injected intrathoracically with *p400*-targeting dsRNA (dsp400) or control *lacZ*-targeting dsRNA (dsLacZ). Mosquitoes were fed with a blood meal containing SFV4 at 4 days post-dsRNA injection (pdi). At 3 days postinfection (pi), RNA was extracted from whole females. Knockdown efficiency and virus genome levels were determined by RT-qPCR. The knockdown of *p400* transcript expression was confirmed (Fig. 3A) and resulted in a significant increase in SFV RNA levels in whole females (Fig. 3B), confirming the role of p400 in inhibiting SFV replication in *A. aegypti* female mosquitoes. The results were repeated in a second independent experiment (see Fig. S1 in the supplemental material).

**p400 shows antiviral activity against SFV, CHIKV, and BUNV.** To determine if the antiviral action of p400 was specific to SFV or if it has broader antiviral activity, we



**FIG 2** Detection of p400 protein in tissues of NBF *A. aegypti* females. Expression of p400 was analyzed in perfused hemocytes (A to C), salivary glands (D), digestive tracts (E to I), and ovaries (J to P) by immunofluorescence assay using an anti-p400 antibody. The signal was determined using an Alexa Fluor 568 goat anti-mouse IgG (H+L) (red). Nuclei are stained by DAPI (blue signal), and F-actin is stained by phalloidin 488 (green signal). Images were acquired on a Zeiss LSM 710 inverted confocal microscope with 40 $\times$ , 63 $\times$ , and 100 $\times$  oil immersion objectives. Scale bars are 5  $\mu$ m (A to C, F to H, and N to P) and 40  $\mu$ m (D, E, and I to M). (A) Perfused prohemocyte. (B and C) Perfused differentiated hemocytes. (D) Salivary glands. (E) Crop. (F to H) Enlargement of panel E. (I) Midgut. (J) Oviduct. (K and L) Ovarioles showing the germarium and primary follicle (pf). (M) Ovarioles surrounded by the ovarian sheath. (N to P) Enlargement of panel M. Yellow star, developing cyst in the germarium; yellow arrowhead, germ line stem cells. The cystoblast is located between the germ line stem cells and the developing cyst. Images shown are representative of a minimum of 10 tissues per experiment from 3 independent experiments.

tested the effect of p400 knockdown on three other arboviruses belonging to different families, the SFV-related alphavirus CHIKV, the bunyavirus BUNV, and the flavivirus ZIKV. For this experiment, *A. aegypti*-derived Aag2 cells were used, and the effect of the p400 knockdown on SFV was used as a positive control. The reporter viruses used for these experiments were CHIKV-2SG-*FFLuc* (*FFLuc*, firefly luciferase expressing), BUNV-NLuc and ZIKV-NLuc (both NLuc, Nano luciferase expressing), and SFV4(3H)-*FFLuc* (also firefly luciferase expressing) (25, 29, 35, 40). Aag2 cells were transfected with *dsp400*-targeting or control dsRNA-targeting enhanced green fluorescent protein (*dseGFP*). Cells were infected with CHIKV-2SG-*FFLuc*, BUNV-NLuc, ZIKV-NLuc, or SFV4(3H)-*FFLuc* at 24 h posttransfection (pt). SFV- and CHIKV-infected cells were lysed 24 hpi, BUNV-infected cells were lysed at 48 hpi, and ZIKV-infected cells were lysed at 72 hpi, and luciferase activity was determined. The time posttransfection at which cells were collected was chosen based on previous studies (29, 34, 35, 41). Knockdown of *p400* (Fig. 4A) resulted in a significant increase in SFV (Fig. 4B), confirming our results obtained *in vivo*, as well as on CHIKV (Fig. 4C) and BUNV (Fig. 4D) replication. However, p400 knockdown had no significant effect on ZIKV, possibly due to higher variation of luciferase expression across replicates for this virus (Fig. 4E). To ensure that the absence of an effect on ZIKV




**FIG 3** *p400* knockdown significantly enhances replication of SFV in *A. aegypti* females. *p400* and SFV expression in whole dsLacZ- or dsp400-injected females 3 days after an SFV4-infected blood meal were analyzed by RT-qPCR. Normalized expression-per-sample values were calculated as described by Taylor et al. (78) in order to obtain normalized expression values, relative to the ribosomal S7 transcript as reference, with a geomean of 1 for the dsLacZ control group. Bars represent the geomean and 95% confidence intervals from  $n = 73$  dsLacZ and  $n = 66$  dsp400. The results were analyzed using a Mann-Whitney test using  $\log_2$ -normalized expression values. This experiment is representative of two independent biological replicates (second replicate shown in Fig. S1). (A) *p400* transcript levels are significantly reduced in dsp400-injected females compared to that in dsLacZ-injected females (mean fold change, 1.7; geomean fold change, 1.6; \*\*\*\*,  $P < 0.0001$ ). (B) SFV4 titers are significantly higher in dsp400-injected females than in dsLacZ-injected ones (mean fold change, 5.3; geomean fold change, 10.1; \*\*\*\*,  $P < 0.0001$ ). A base 10 log scale is used for the y axis.

was not due to the time of sampling, a time course of *p400* knockdown and ZIKV infection was performed with samples analyzed at 24, 48, and 72 hpi. *p400* expression was significantly reduced at all time points (Fig. S2A); however, luciferase expression was not changed at any time point assessed (Fig. S2B).

**p400 is required for exo-siRNA pathway activity and regulates levels of *ago-2* *in vivo*.** As *p400* had previously been identified as being a component of the exo-siRNA pathway in *D. melanogaster*-derived S2 cells (42), and we have shown here that it affects arbovirus replication both *in vitro* and *in vivo*, we sought to determine if the antiviral action of *p400* could be due to an effect on the exo-siRNA pathway-silencing activity in *A. aegypti*. In order to determine if *p400* was important for exo-siRNA pathway activity, reporter assays were performed. Aag2 cells were transfected with pIZ-FLuc (expressing the silencing target *FFLuc*), pAcIE1-RLuc (as an internal transfection control, expressing *Renilla* luciferase), and dsp400 or dseGFP (control). At 24 hpt, cells were transfected again with dsRNA targeting either eGFP (control) or *FFLuc* (dsFFLuc). Cells were lysed 24 h after the second transfection, and luciferase activity was determined. While the introduction of dsFFLuc in cells treated with dseGFP significantly decreased *FFLuc* expression, silencing of the *FFLuc* reporter plasmid after the introduction of dsFFLuc was abolished in the presence of *p400*-targeting dsRNA (Fig. 5), showing that *p400* is required for the activity of the exo-siRNA pathway.


Next, we aimed to identify what role *p400* might play in the exo-siRNA pathway. In human cells, *p400* is part of the Tip60 complex and is involved in transcriptional regulation through chromatin remodeling (43). We therefore reasoned that *p400* may play a regulatory role in the exo-siRNA pathway at the transcriptional level. In order to test this hypothesis, we investigated the expression levels of the exo-siRNA effector *Ago-2* in SFV4-infected females following the knockdown of *p400*. The female mosquitoes injected with LacZ (control) or *p400*-targeting dsRNA and given a blood meal containing SFV4 at 4 days pdi (used in Fig. 3B) were further analyzed for this purpose. RT-qPCR was performed to assess transcript levels in whole females at 3 dpi. As shown in Fig. 6A, *ago-2* transcript expression levels in whole females were significantly reduced upon *p400* transcript knockdown *in vivo*. As described previously, the results were repeated in a second independent experiment (Fig. S1). Similarly, *ago-2* transcript expression levels were also reduced in whole noninfected, NBF females following knockdown of *p400* transcripts (Fig. 6B). In contrast, knockdown of *p400* had no significant effect on *dcr-2* transcript levels.



**FIG 4** *p400* knockdown significantly enhances replication of SFV, CHIKV, and BUNV but not ZIKV. (A) *p400* knockdown efficiency in Aag2 cells was analyzed by RT-qPCR using the  $2^{-\Delta\Delta CT}$  method and *p400* expression calculated relative to eGFP dsRNA transfection. Bars show the fold change in gene expression from 3 independent experiments (3 wells in each independent experiment, with an average of three wells per condition/experiment used for statistical analysis). Error bars represent the minimum and maximum fold change. The results were analyzed by a one-sample *t* test. *p400* transcript levels are significantly reduced after dsp400 transfection ( $P = 0.039$ ; \*,  $P < 0.05$ ). The effect of *p400* knockdown on SFV-*FFLuc* (B), CHIKV-2SG-*FFLuc* (C), BUNV-NLuc (D), and ZIKV-NLuc (E) was assessed by a luciferase assay. Bars show the means of the results from 3 independent experiments (3 wells in each independent experiment, with the average of three replicates per condition/experiment used for statistical analysis). Values were calculated relative to the control eGFP dsRNA-transfected sample, which was set to 1. Statistical significance was determined by performing a one-sample *t* test (SFV  $P = 0.0129$ , CHIKV  $P = 0.0286$ , and BUNV  $P = 0.0257$ ; \*,  $P < 0.05$ ). Error bars show the standard error of mean.

## DISCUSSION


In this study, we found that *p400*, an ortholog of the TIP60 complex *D. melanogaster* protein Domino, is antiviral against the arbovirus SFV in both *A. aegypti* mosquito-derived cells in culture and adult females. We show that *p400* is also antiviral against the related alphavirus CHIKV as well as the bunyavirus BUNV. As already discussed, antiviral activity against WNV (a mosquito-borne flavivirus; *Flaviviridae*) and VSV (*Rhabdoviridae*) has previously been attributed to the *p400* ortholog Domino in *D. melanogaster*-derived DL1 cells following a dsRNA screen for antiviral proteins (38). The knockdown of other members of the Tip60 complex (RuvBL1, RuvBL2, and Tip60) in mosquito cells was also shown to increase WNV and VSV replication (38), suggesting that *p400*/Tip60 has broad and conserved antiviral activity in dipterans. In mammals,



**FIG 5** *p400* knockdown leads to reduced silencing efficiency. RNA silencing activity in the presence of *p400* knockdown was determined using a sensor assay. Aag2 cells were transfected with plasmids constitutively expressing firefly (*FFLuc*) or *Renilla* luciferase and dsRNA targeting either *p400* or eGFP as a control. At 24 h post-initial transfection, dsRNA against *FFLuc* or eGFP was transfected. Silencing activity was assessed by measuring the relative levels of *FFLuc* 24 h post-second transfection after normalization to *RLuc* (internal transfection control) levels. The level of silencing was calculated relative to respective control eGFP dsRNA-transfected samples (dseGFP+dseGFP as a control for condition dseGFP+dsFFLuc, and dsp400+dseGFP as a control for condition dsp400+dsFFLuc), which were set to 1. Bars show the means from 3 independent experiments (3 wells in each independent experiment, average of three wells per condition/experiment used for statistical analysis). Error bars show the standard error of mean. Significance was determined by an unpaired *t* test to determine the *P* value ( $P = 0.034$ ; \*,  $P < 0.05$ ).

Tip60 has been reported to have antiviral activity against adenovirus (44). In contrast, Tip60 can also promote infections with human papillomavirus (45, 46), human immunodeficiency virus 1 (47, 48), and herpesviruses (46, 49). Therefore, the action of the Tip60 complex, including *p400*, appears to have a positive or negative effect on virus infection depending on the biological system and virus.

We further show that *p400* is required for the activity of the exo-siRNA pathway. Our results are consistent with a previous study in *D. melanogaster*-derived S2 cells in which Domino was identified as a regulator of the siRNA pathway (42). As the exo-siRNA



**FIG 6** Effect of *p400* knockdown on *ago-2* and *dcr-2* transcript levels in *A. aegypti* females. (A) *ago-2* transcript levels in whole dsLacZ- or dsp400-injected females 3 days after an SFV4-infected blood meal was analyzed by RT-qPCR. Normalized expression-per-sample values were obtained as described by Taylor et al. (78) in order to obtain normalized expression values, relative to the ribosomal S7 transcript as a reference, with a geomean of 1 for the dsLacZ control group. Bars show the geomean and 95% confidence intervals from  $n = 73$  dsLacZ and  $n = 66$  dsp400 females of a single experiment, also used in Fig. 3. This experiment is representative of two independent experiments (second replicate shown in Fig. S1). The results were analyzed using a Mann-Whitney test using  $\log_2$ -normalized expression values. *ago-2* transcript levels are significantly reduced in dsp400-injected females compared to those in dsLacZ-injected ones (mean fold change, 1.2; geomean fold change, 1.1;  $P = 0.0197$ ; \*,  $P < 0.05$ ). (B) Transcript levels of *p400*, *ago-2*, and *dcr-2* in whole non-blood-fed (NBF) females 4 days after injection with dsLacZ or dsp400 were analyzed by RT-qPCR using the  $2^{-\Delta\Delta CT}$  method and expression in dsLacZ females as the reference sample. Bars represent the fold change in gene expression (3 independent biological replicates, with pools of 10 females per replicate). Error bars show the minimum and maximum fold change. The results were analyzed using a one-sample *t* test. *p400* and *ago-2* transcript levels are significantly reduced in dsp400-injected females compared to those in dsLacZ-injected females (70% reduction,  $P = 0.0047$ ; and 42% reduction,  $P = 0.0067$ ; \*\*,  $P < 0.01$ ).

pathway limits SFV, BUNV, and CHIKV infection in mosquitoes (22, 23, 35), the action of p400 against these viruses is likely to be mediated at least in part through this antiviral pathway. In *D. melanogaster*, Domino is required for dipterin induction in the fat body (50). Moreover, homozygous *dom* mutant *D. melanogaster* larvae do not contain hemocytes and do not survive after pupariation, illustrating the important role that Domino has in immunity (51). Roles of this protein also extend to cell proliferation/growth and death (52, 53) and maintaining repression of proapoptotic genes (54). In mammals, Tip60 has been reported to be antiviral by suppressing adenovirus gene expression through binding to the immediate early promoter (44). Considering the different roles of p400 previously described, we cannot therefore exclude that p400 could mediate antiviral effects in *A. aegypti* mosquitoes through other mechanisms in addition to its role in the exo-siRNA pathway.

Consistent with our finding that p400 regulates *ago-2* transcript levels, p400/Domino is a chromatin-remodeling ATPase member of the Tip60 complex involved in transcriptional regulation and chromatin modification in the fly model but also in human cells (43, 55, 56). In human cells, Tip60/p400 complexes catalyze the incorporation of the histone variant H2A.Z within chromatin, including promoter regions to modulate gene expression in response to diverse cellular cues (57). As Ago-2 is a main effector in the exo-siRNA pathway, the action of p400 on this pathway activity is likely to be mediated through the regulation of *ago-2* expression. This could also be the reason why Domino is required for the Ago-2-dependent RNA interference (RNAi) activity in *D. melanogaster*-derived S2 cells (42). While p400 regulates *ago-2* transcript levels, p400 knockdown does not have any significant impact on the transcript levels of another important exo-siRNA pathway component, *dcr-2*. Previous reports have shown that Ago-2 is antiviral against SFV, BUNV, and CHIKV (22, 23, 35), while we and others have shown that reduced or absent Ago-2 activity does not result in an increase in ZIKV replication (34, 58, 59). Altogether, this could explain why p400 is antiviral against SFV, BUNV, and CHIKV, while we could not detect any significant effect against ZIKV. As previously discussed, p400 is an ATPase part of the Tip60 chromatin remodeling complex (43, 55, 56). Although the effect of p400 knockdown was not significant on ZIKV, the slight increase in ZIKV expression may indicate that p400 could regulate the expression of other antiviral genes in addition to *ago-2*. Outside antiviral responses, p400 knockdown could even disturb virus replication in other ways, such as changes in the expression of host factors.

We found that *p400* was expressed across various tissues in non-blood-fed females, with the strongest expression in ovaries. In the germarium, the protein is detected in both the germ line and somatic cells, more predominantly in the germ line stem cells and developing secondary follicle. In the primary previtellogenic follicle, p400 is slightly expressed in some somatic epithelial cells. This is similar to the ovarian expression pattern of the two alternative splicing isoforms, DomA and DomB, in *D. melanogaster* adult females (60), with an expression in the developing cysts within the germarium and little to no expression at stages 7 to 8 (corresponding to the primary follicle arrested at the previtellogenic stage in mosquitoes). In the fruit fly, Domino is required for oogenesis, more particularly for somatic and germ line stem cell maintenance as well as cystocyte differentiation (56, 61, 62). In humans, there are two homologues of Domino, p400 and SRCAP. Interestingly, SRCAP can rescue the female sterility of hypomorphic *dom* alleles in *D. melanogaster* (63), showing functional conservation of these SWR1-like remodelers during evolution. Due to the similar localization in ovaries of *Aedes* and *Drosophila* spp., it is likely that p400 in mosquitoes and Domino in flies exert similar functions during oogenesis. The protein p400 is also expressed in the large nucleus of the ovarian sheath cells, as well as in the nucleus of the cells forming the crop, suggesting a role in transcriptional regulation in these cells. We also found p400 expressed in tracheae surrounding various tissues, including salivary glands, digestive tract, and ovaries. Interestingly, the von Hippel-Lindau tumor suppressor gene (VHL) regulates the expression of p400 posttranscriptionally in mouse embryonic fibroblasts to prevent senescence (64). In *D. melanogaster*, VHL regulates



tracheal branch migration and lumen formation through endocytosis (65). The presence of p400 in the mosquito tracheal system could indicate that it is involved in tracheal morphogenesis. As arboviruses can infect tracheal cells in *A. aegypti* (66), p400 could also mediate antiviral protection in these cells. Consistent with its role in hemocyte proliferation and differentiation in the fly model (51), p400 is expressed in hemocytes in *A. aegypti* females, with the protein localized in the nucleus of undifferentiated prohemocytes and in the nucleus and cytoplasm of differentiated hemocytes. In *D. melanogaster*, hemocytes control viral infections by clearing virus-infected cells by phagocytosis (67, 68) and by providing an Ago-2-dependent protection to naive cells (69), resulting in higher viral loads in flies depleted of hemocytes. Consequently, p400 could indirectly control viral loads in *A. aegypti* due to a role in immune cell differentiation. Hemocytes can be infected by viruses *in vivo* in mosquitoes (27, 70); therefore, the antiviral action of p400 could be directly mediated through Ago-2, though we cannot exclude other mechanisms. In the absence of genetic tools to drive p400 knockdown in a tissue-specific manner in mosquitoes, it is difficult to conclude with certitude *in vivo* in which tissues/cells p400 is antiviral.

The exo-siRNA pathway is one of the key antiviral immune pathways in mosquitoes (8, 16, 19). Despite the importance of this pathway in antiviral defense, there is a considerable lack of understanding regarding how the pathway is regulated. Here, we show a role of p400 in the regulation of *ago-2* transcript levels (and subsequently, the activity of the exo-siRNA pathway) and the antiviral response in *A. aegypti*. In addition to extending the diverse functions of p400, it could explain the previous observations of Domino's antiviral activity in *D. melanogaster* cells and its role in regulating the exo-siRNA pathway. Further studies will need to determine if and how exo-siRNA pathway activity is differentially regulated across tissues in *A. aegypti* and whether this is relevant for the transmission of arboviruses. In addition, more work will be necessary to understand the mechanism by which p400 is antiviral. This could include interaction studies with other cellular proteins, as well as promoter binding studies to assess the wider mode of action of this protein, which might explain how *ago-2* levels are controlled by p400. The tools used in this study (primers, dsRNA, and antibody) target the four p400 splicing isoforms predicted in *A. aegypti* genome annotation (AaegL5). As there are two splicing isoforms, DomA and DomB, in *D. melanogaster* with distinct functions during oogenesis (60), it would be interesting to identify which isoform is involved in the exo-siRNA pathway regulation and antiviral activity in these species. Future work on p400 in *A. aegypti* will have to investigate these key questions on its mode of action and activity across tissues.

## MATERIALS AND METHODS

**Cell culture.** *A. aegypti*-derived Aag2 cells (obtained from P. Eggleston, Keele University, UK) were cultured in Leibowitz L-15 medium supplemented with 10% fetal bovine serum (FBS; Gibco), 10% tryptose phosphate broth (TPB), and penicillin-streptomycin. Baby hamster kidney 21 (BHK-21) cells (a commonly used cell line available at the MRC-University of Glasgow Centre for Virus Research) were cultured in Glasgow minimum essential medium (GMEM), 10% newborn calf serum (NBCS) or FBS, 10% TPB, and penicillin-streptomycin. A549 (human lung adenocarcinoma) NPro cells (a gift of R. E. Randall, University of St. Andrews, UK) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS and penicillin-streptomycin, and the presence of bovine viral diarrhoea virus (BVDV)-derived NPro, which targets interferon regulatory factor 3 (IRF3) for degradation (71), was maintained by the addition of blasticidin (10  $\mu$ g/ml). Aag2 cells were maintained at 28°C and BHK-21 and A549 NPro cells at 37°C with 5% CO<sub>2</sub>.

**Mosquito rearing.** *A. aegypti* Liverpool strain (a gift from E. Devaney, University of Glasgow, UK) was reared at 28°C and 80% humidity with a 12:12 light photoperiod. Larvae were reared in water and fed on dry cat food from larvae hatching to the pupal stage. The emerging adult mosquitoes were removed and put in cages with unlimited access to 10% (wt/vol) sucrose solution. For mass rearing, female mosquitoes were fed on heparinized rabbit blood (Orygen Antibodies Ltd.) using a Hemotek system (Hemotek Ltd., UK).

**Reporter virus stocks, plaque assay titration, and infection.** Luciferase expressing SFV4 contains *FFLuc* inserted between nsP3 and nsP4 using duplicated nsP2 cleavage sites, as previously described (25, 72). pCMV-SFV4(3H)-*FFLuc* was electroporated into BHK-21 cells and incubated at 37°C until extensive cell death was visible. The cell supernatant was harvested and clarified by centrifugation. The resulting virus stock was stored at -80°C. CHIKV expressing *FFLuc* between the nonstructural and structural open reading frames under a duplicated subgenomic promoter, CHIKV-2SG-*FFLuc* (25), was rescued by

transfection of *in vitro*-transcribed RNA into BHK-21 cells. For this, pSP6-ICRES1-2SG-*FFLuc* was linearized and *in vitro* transcribed using the SP6 MEGAscript kit (Thermo Fisher Scientific), along with Ribo m7G Cap Analog (Promega), followed by transfection into BHK-21 cells using Lipofectamine 2000 (Thermo Fisher Scientific), following the manufacturer's instructions. The supernatant was collected, clarified by centrifugation, and stored at  $-80^{\circ}\text{C}$ . SFV4(3H)-*FFLuc* and CHIKV-2SG-*FFLuc* were titrated on BHK-21 cells by making 10-fold serial dilutions and overlaying the inoculum with 0.6% Avicel in minimum essential medium (MEM) containing 2% FBS and incubating at  $37^{\circ}\text{C}$  for 72 h. Cells were fixed using 10% formalin (Sigma) and stained with 0.1% toluidine blue. NLuc-expressing BUNV was grown and titrated as described previously (35). ZIKV-NLuc (40) was grown on A549 NPro cells cultured in DMEM supplemented with 2% FBS and blasticidin ( $2\ \mu\text{g}/\text{ml}$ ) for 5 days at  $37^{\circ}\text{C}$  with 5%  $\text{CO}_2$ . Virus supernatant was collected and cleared by centrifugation at  $3,220 \times g$  for 10 min, followed by storage at  $-80^{\circ}\text{C}$ . For virus titration, cell monolayers of A549 NPro were infected with serially diluted ZIKV-NLuc in DMEM with 2% FBS and incubated with an overlay consisting of MEM with 4% FBS, 4% HEPES, and 1.2% Avicel for 5 days. Infected cells were fixed with 4% formaldehyde and stained with 0.2% bromophenol to visualize plaques. Aag2 cells were infected by removing the culture medium, overlaying with  $200\ \mu\text{l}$  virus-containing inoculum, and incubating at  $28^{\circ}\text{C}$  for 1 h. The inoculum was removed and replaced with complete medium, followed by incubation at  $28^{\circ}\text{C}$ .

Aag2 cell infections were carried out with CHIKV-2SG-*FFLuc* at a multiplicity of infection (MOI) of 0.02, with SFV4(3H)-*FFLuc* at an MOI of 0.1, with BUNV-NLuc at an MOI of 0.01, or with ZIKV-NLuc at an MOI of 0.01 24 h posttransfection (hpt). SFV- and CHIKV-infected cells were lysed at 24 hpi, BUNV-infected cells were lysed at 48 hpi, and ZIKV-infected cells were lysed at 72 hpi, and luciferase activity was measured.

**SFV production for oral infection of mosquitoes.** SFV4 was produced from plasmid pCMV-SFV4, as described previously (73). Briefly, the plasmid was transfected using Lipofectamine 2000 (Thermo Fisher Scientific) into BHK-21 cells grown in GMEM with 2% FBS and 10% TPB at  $37^{\circ}\text{C}$  with 5%  $\text{CO}_2$ . The virus was titrated by a plaque assay on BHK-21 cells, as described above.

**Plasmids.** The pIZ-FLuc and pAcIE1-RLuc plasmids have been previously described (74, 75). The plasmid pPub-V5MBP was synthesized by subcloning maltose-binding protein (MBP) from pcDNA-DEST40-MBP-hDVR (75) into the mosquito expression vector pPub (29), based on an expression construct containing the *A. aegypti* polyubiquitin promoter (76). The plasmid pUC57-p400 was synthesized (GenScript) and contains the *A. aegypti* coding sequence, as indicated in VectorBase with accession number AAEL001440 (assembly AaegL1). In the AaegL5 assembly, AAEL001440 was changed to AAEL027494 (transcript identifiers [IDs] RA to RD; all transcripts targeted by dsp400). The p400 coding sequence was further subcloned into the pPub expression vector. The V5 tag was added to the N terminus of pPub-MBP and pPub-p400 clones using the Infusion cloning technique (Clontech) to give pPub-V5MBP and pPub-V5p400, respectively.

**dsRNA synthesis for *in vitro* experiments.** RNA was extracted from Aag2 cells using TRIzol (Thermo Fisher Scientific), following the manufacturer's guidelines. One microgram of RNA was reverse transcribed using SuperScript III (Thermo Fisher Scientific) and an oligo(dT)15 primer (Promega), according to the manufacturer's instructions. Unique portions of candidate genes were amplified from cDNA with primers containing T7 RNA polymerase minimal promoter sequence overhangs using GoTaq G2 Flexi polymerase (Promega). PCR products were sequenced for target verification before the production of dsRNA. For the production of dsGFP (used as a control), specific primers with T7 RNA polymerase promoter sequences were used to amplify a unique portion of eGFP from a plasmid template containing the eGFP-encoding gene. All primer sequences are listed in Table S1. The MEGAscript RNAi kit (Thermo Fisher Scientific) was used to synthesize dsRNA from the PCR fragments, according to the manufacturer's guidelines.

**dsRNA synthesis and purification for *in vivo* experiments.** Total RNA was extracted with TRIzol (Thermo Fisher Scientific) from whole NBF *A. aegypti* females, according to the manufacturer's instructions, including DNase treatment (Turbo DNase; Ambion). cDNA was generated from  $1\ \mu\text{g}$  of total RNA using SuperScript III reverse transcriptase (Thermo Fisher Scientific) and oligo(dT)15. cDNAs were further amplified with KOD Hot Start master mix (EMD Millipore). p400-specific primers (Table S1) with a T7 RNA polymerase promoter sequence were used to amplify a p400-derived fragment (same primers used for *in vitro* and *in vivo* experiments) and further purified using the QIAquick gel extraction kit (Qiagen). After sequencing, the PCR product was used as the template for a second PCR using the same primers and polymerase. For the production of dsLacZ (used as control dsRNA), specific primers with T7 RNA polymerase promoter sequences were used to amplify a *lacZ*-derived fragment from plasmid template *Drosophila/act5C-βGal* (stock number 1220 obtained from DGRC) containing the *Escherichia coli lacZ* gene. dsRNAs were synthesized and purified using the MEGAscript RNAi kit (Thermo Fisher Scientific), according to the manufacturer's instructions. dsRNA was then purified and concentrated to  $10\ \mu\text{g}/\mu\text{l}$  in nuclease-free water using sodium acetate (3 M; Ambion) and ethanol precipitation.

**Transfection of BHK-21 cells.** BHK-21 cells were plated at a density of  $3 \times 10^6$  cells per well in 6-well plates. One microgram of pPub-V5MBP or pPub-V5p400 was transfected the following day using Dharmafect2 (Dharmacon), following the recommended protocol. Cells were collected 24 hpt by trypsinization and plated in slides (ibidi) for immunostaining.

**Transfection of mosquito cells.** Aag2 cells were plated at a density of  $1.7 \times 10^5$  cells per well in a 24-well plate. dsRNA or plasmid DNA was transfected the following day with Lipofectamine 2000 (Thermo Fisher Scientific), using the supplied protocol. The medium was replaced at 4 to 5 hpt. Knockdown experiments were performed by transfecting 100 ng dsRNA into Aag2 cells. Plasmid sensor assays were performed by transfecting 50 ng pIZ-FLuc and 8 ng pAcIE1-RLuc and 100 ng of either

eGFP-targeting or p400-targeting dsRNA. At 24 h post-initial transfection, cells were transfected again with 10 ng FFLuc- or eGFP-targeting dsRNA. The FFLuc and RLuc activities were measured at 24 h post-second transfection.

**Luciferase assay.** Aag2 cells were lysed in  $1\times$  passive lysis buffer (Promega) and lysed by rocking at room temperature for 20 min or stored in  $-20^{\circ}\text{C}$  immediately. FFLuc and Renilla luciferase activities were measured using the dual-luciferase assay system (or Steady-Glo luciferase assay system in the case of CHIKV-2SG-FFLuc) (Promega); NLuc activities were measured by using the Nano-Glo luciferase assay systems (Promega) (ZIKV-NLuc and BUNV-NLuc). All measurements were carried out on Glomax luminometers (Promega).

**Total RNA extraction and RT-qPCR from cells.** For analysis of p400 knockdown efficiency, cells were lysed in TRIzol reagent (Thermo Fisher Scientific) at 24 hpt and extracted according to the manufacturer's instructions. Reverse transcription (RT) was performed using the SuperScript III enzyme kit (Thermo Fisher Scientific) from  $1\ \mu\text{g}$  of RNA in a final volume of  $20\ \mu\text{l}$ . Quantitative PCR (qPCR) was carried out using Fast SYBR green master mix (Applied Biosystems) on a 7500 Fast machine (Applied Biosystems). The primers used are listed in Table S1. Data were analyzed with the 7500 Software v2.0.6, and transcript expression relative to the ribosomal S7 as a reference was calculated according to the  $2^{-\Delta\Delta\text{CT}}$  method (77). The dseGFP control was set to 1, and dsp400 samples were normalized to dseGFP. Data from 3 independent biological replicates were analyzed using a one-sample *t* test (Prism software).

**dsRNA injection into mosquitoes.** At 1 to 2 days after emergence, cold-anesthetized female mosquitoes were injected with dsRNA into their thorax using a nanoinjector (Nanoject II; Drummond Scientific) with  $2\ \mu\text{g}$  of dsRNA (dsp400 or dsLacZ) in  $414\ \text{nl}$  of injection solution. To increase knockdown efficiencies, Cellfectin II transfection reagent (Thermo Fisher Scientific) was added to the injection solution. Briefly, Cellfectin was mixed with Schneider's *Drosophila* medium (1:1 [vol/vol]; Thermo Fisher Scientific); this mix was added to dsRNA solution (1:1 [vol/vol]) previously adjusted with Schneider's medium to give  $2\ \mu\text{g}$  of dsRNA per female/injection volume. The injection solution was then incubated for 15 min at room temperature before injection.

**Mosquito sampling, dissection, and hemocyte perfusion.** To assess the effect of p400 knockdown on *ago-2* transcript levels in whole NBF females and in tissues, female mosquitoes injected with dsRNA (targeting control or p400 transcripts) were sacrificed at 4 days pdi. Whole females (pools of 10 females) and dissected tissues (pools of 25 digestive tracts or ovaries, pools of 60 salivary glands, and pools of perfused hemocytes from 70 females) were further stored in tubes on dry ice before TRIzol was added for RNA extraction. Digestive tracts include the posterior part of the esophagus, dorsal diverticula, crop, midgut, Malpighian tubules, and hindgut. The tissues were carefully dissected from 5-day-old NBF females in RNase-free 0.05% (vol/vol) phosphate-buffered saline with Tween 20 (PBS-T) and either placed into tubes on dry ice before TRIzol was added for subsequent analysis of p400 and *ago-2* tissue levels by qPCR or added into 0.05% PBS-T on wet ice for fixation and immunostaining. Hemocytes were collected by perfusion. Briefly, the last segment of the abdomen was cut, and mosquitoes were then injected in the thorax with 0.01% PBS-T using a glass capillary mounted on a syringe. For RT-qPCR experiments, PBS-T-diluted hemocytes were collected in tubes on ice and centrifuged at  $375\times g$  for 15 min at  $4^{\circ}\text{C}$ . The supernatant was gently removed before adding TRIzol. For immunostaining, hemocytes were perfused on slides (ibidi; 5 females per well, 4 wells per replicate). The slides were left for 30 min at  $28^{\circ}\text{C}$  before removal of PBS-T and fixation.

**Antibody production.** The Peptide Supplied Polyclonal Antibody Package (mouse; catalog no. SC1046) available from GenScript USA, Inc. was used to produce the p400 antibody. Peptide optimization was performed using the OptimumAntigen design program provided by GenScript. The peptide GMN KPKAIQDQNTSC (present in proteins AAEL027494-RA to AAEL027494-RD) was selected and conjugated to keyhole limpet hemocyanin (KLH) for immunization into five BALB/c mice. Antiserum from mouse 5 was used in these experiments. The specificity of the antibody was confirmed by colocalization of p400 and V5 antibody signals in BHK-21 cells transfected with pPub-V5p400 (Fig. S3). Further details on antibody production are available upon request.

**Immunofluorescence analysis of mosquito tissues, hemocytes, and BHK-21 cells.** Salivary glands and ovaries (minimum of  $n = 10$  each for 1 experiment for 3 independent experiments) were fixed at room temperature (RT) for 20 min in 4% (w/vol) paraformaldehyde (PFA) diluted in 0.05% PBS-T. BHK-21 cells (2 independent experiments), perfused hemocytes, and digestive tract tissues ( $n = 10$  minimum for 1 experiment for 3 independent experiments) were fixed in the same way, except that PFA was diluted using PBS. Fixed cells/tissues (except ovaries) were washed (three times for 15 min each at  $4^{\circ}\text{C}$ ) in 0.05% PBS-T before blocking for at least 30 min in blocking solution (0.05% PBS-T, 5% [vol/vol] fetal calf serum [FCS], 5% [wt/vol] bovine serum albumin [BSA], 0.05% [vol/vol] Triton X-100) at  $4^{\circ}\text{C}$ . Unlike other tissues, ovaries were dilacerated and washed in 1% PBS-T before being blocked in blocking solution containing 0.5% (vol/vol) Tween and 0.5% (vol/vol) Triton X-100. Cells/tissues were incubated at  $4^{\circ}\text{C}$  overnight with a mouse anti-p400 antibody (see below) diluted 1:200 or a rabbit anti-V5 (Abcam) at 1:500 in blocking solution. For each experiment, a negative control without primary antibody was carried out (Fig. S4). Samples were washed (five times for 15 min each at  $4^{\circ}\text{C}$ ) in 0.05% PBS-T (0.5% PBS-T for ovaries) and incubated with an Alexa Fluor 568 goat anti-mouse IgG (H+L) or an Alexa Fluor 488 goat anti-rabbit IgG (H+L) diluted 1:1,000,  $1\times$  4',6-diamidino-2-phenylindole (DAPI) (405 nm), and  $1\times$  phalloidin (488 or 647 nm) in blocking solution for 2 h at RT. Four washes in 0.05% PBS-T (0.5% PBS-T for ovaries) were carried out. Tissues were mounted between the slide and coverslip (24 mm by 24 mm) with an imaging spacer (1 well, 13-mm diameter, 0.12-mm thickness, Grace Bio-Labs SecureSeal imaging spacer; Sigma-Aldrich) using mounting medium (ibidi). Mounting medium was used to replace PBS-T in hemocyte- or BHK-21-containing wells. Images were acquired on a Zeiss LSM 710 inverted confocal microscope,

equipped with a 40×, 63×, or 100× oil immersion objective, and processed with Fiji/ImageJ and Adobe Photoshop.

**Blood meal infection of mosquitoes with SFV.** At 4 days pdi, *A. aegypti* females were allowed to feed for 30 min on blood meal containing SFV4. Fresh rabbit blood (Orygen Antibodies Ltd.) was washed with PBS to remove white blood cells and serum. PBS was then added to the red blood cell fraction to return to the initial blood volume. The infectious blood meal was prepared with 2/3 of washed blood and 1/3 of SFV-containing culture medium to give a final titer of  $5.10^7$  PFU/ml, supplemented with 2 mM ATP. Only engorged females were kept further in the presence of 10% sucrose at 28°C and 80% humidity. At 3 days postfeeding, females were sampled individually before RNA extraction.

**Total RNA extraction and RT-qPCR from mosquitoes.** Dissected tissues or whole females were homogenized in TRIzol reagent with glass beads using the Precellys 24 homogenizer (Bertin Instruments). RNA from tissues, whole females, and hemocytes was extracted according to the manufacturer's instructions, except that 1-bromo-3-chloropropane was used instead of chloroform, and DNase (Turbo DNase; Ambion) treatment was carried out. Reverse transcription (RT) was performed using the Moloney murine leukemia virus (MMLV) retrotranscriptase (Promega) from 1 to 2 μg of RNA in a final volume of 40 μl. cDNA was aliquoted and further stored at -20°C until qPCR was carried out using Fast SYBR green master mix (Applied Biosystems) on a 7500 Fast machine (Applied Biosystems). The primers used are listed in Table S1. Data were analyzed with the 7500 Software v2.0.6.

For analysis of *p400* expression, transcript expression relative to the ribosomal S7 transcript as a reference was calculated according to the  $2^{-\Delta\Delta CT}$  method (77). The hemocyte sample was set to 1, and other samples were normalized to the hemocyte sample. Data were obtained from 3 independent biological replicates. For analysis of *p400* knockdown efficiency and the effect on *ago-2* levels in whole NBF females, transcript expression relative to the ribosomal S7 transcript as a reference was calculated according to the  $2^{-\Delta\Delta CT}$  method (77). The dsLacZ control was set to 1, and dsp400 samples were normalized to dsLacZ. Data from 3 independent biological replicates (pool of 10 females per replicate) were analyzed by a one-sample *t* test (Prism software). For analysis of *p400* knockdown and the effect on *ago-2* levels and SFV infection, data were analyzed as described by Taylor et al. (78) in order to obtain normalized expression values, relative to the ribosomal S7 transcript as a reference, with a geometric mean (geomean) of 1 for the dsLacZ control group (two independent experiments;  $n = 73$  females for dsLacZ and 66 for dsp400 in Fig. 3A and B and 6A;  $n = 39$  females for dsLacZ and 43 for dsp400 in Fig. S1). Log<sub>2</sub>-normalized expression values were analyzed using a Mann-Whitney test (with the Prism software).

**Data availability.** The data sets generated and analyzed during the current study are available in the University of Glasgow repository at <https://doi.org/10.5525/gla.researchdata.705>.

## SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

**FIG S1**, TIF file, 0.1 MB.

**FIG S2**, TIF file, 0.1 MB.

**FIG S3**, TIF file, 2.6 MB.

**FIG S4**, TIF file, 1 MB.

**TABLE S1**, DOCX file, 0.1 MB.

## ACKNOWLEDGMENTS

We acknowledge A. Merits (University of Tartu, Estonia) and the *Drosophila* Genomics Resource Center (DGRC; supported by NIH grant 2P40OD010949) for reagents, as well as M. Chase-Topping (University of Edinburgh, UK) for help with data analysis.

We declare no conflicts of interest.

Conceptualization, M.M., F.A., E.P., E.S., A.-B.F., and A.K.; methodology, M.M., F.A., C.L.D., M. Varjak, M. Vazeille, A.-B.F., E.P., E.S., A.K.; formal analysis, M.M., F.A., M. Varjak, E.P., E.S., A.K., and B.W.; investigation, M.M., F.A., E.P., C.L.D., M.L., J.K., C.L., S.T., A.M., M. Varjak, M. Vazeille, and R.J.G.; validation, M.M., F.A., E.P., C.L.D., M.L., J.K., A.M., and M. Varjak; resources, M. Vazeille, A.-B.F., I.D., and R.J.G.; writing—original draft preparation, M.M., F.A., E.P., and A.K.; writing—review and editing, M.M., F.A., C.L.D., M. Varjak, M. Vazeille, M.L., A.M., A.-B.F., J.K., E.S., E.P., and A.K.; visualization, M.M., F.A., E.P., and A.K.; data curation, M.M., F.A., E.P., and A.K.; supervision, A.K., E.P., and E.S.; project administration, A.K., E.P., and E.S.; funding acquisition, A.K., E.S., and E.P.

This work was funded by the UK Medical Research Council (grant MC\_UU\_12014/8 to A.K., E.S., and E.P.), Institut Pasteur (to M. Vazeille and A.-B.F.), and the French Government's Investissements d'Avenir program, Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases" (grant ANR-10-LABX-62-IBEID to A.-B.F.). R.J.G. was supported by a British Council Newton Fund grant, 279705176, under the DOST-Newton Ph.D. Scholarship partnership; the grant is funded by the UK Department for Business, Energy and Industrial Strategy, Philippines Department of Science and

Technology-Science Education Institute, and the University of the Philippines Visayas and delivered by the British Council. For further information, please visit <http://www.newtonfund.ac.uk/>.

## REFERENCES

- Weaver SC, Reisen WK. 2010. Present and future arboviral threats. *Antiviral Res* 85:328–345. <https://doi.org/10.1016/j.antiviral.2009.10.008>.
- Weaver SC, Costa F, Garcia-Blanco MA, Ko AI, Ribeiro GS, Saade G, Shi PY, Vasilakis N. 2016. Zika virus: history, emergence, biology, and prospects for control. *Antiviral Res* 130:69–80. <https://doi.org/10.1016/j.antiviral.2016.03.010>.
- Linthicum KJ, Britch SC, Anyamba A. 2016. Rift Valley fever: an emerging mosquito-borne disease. *Annu Rev Entomol* 61:395–415. <https://doi.org/10.1146/annurev-ento-010715-023819>.
- Mayer SV, Tesh RB, Vasilakis N. 2017. The emergence of arthropod-borne viral diseases: a global prospective on dengue, chikungunya and Zika fevers. *Acta Trop* 166:155–163. <https://doi.org/10.1016/j.actatropica.2016.11.020>.
- Paixão ES, Teixeira MG, Rodrigues LC. 2018. Zika, chikungunya and dengue: the causes and threats of new and re-emerging arboviral diseases. *BMJ Glob Health* 3:e000530. <https://doi.org/10.1136/bmjgh-2017-000530>.
- Wilder-Smith A, Gubler DJ, Weaver SC, Monath TP, Heymann DL, Scott TW. 2017. Epidemic arboviral diseases: priorities for research and public health. *Lancet Infect Dis* 17:e101–e106. [https://doi.org/10.1016/S1473-3099\(16\)30518-7](https://doi.org/10.1016/S1473-3099(16)30518-7).
- Kean J, Rainey SM, McFarlane M, Donald CL, Schnettler E, Kohl A, Pondeville E. 2015. Fighting arbovirus transmission: natural and engineered control of vector competence in *Aedes* mosquitoes. *Insects* 6:236–278. <https://doi.org/10.3390/insects6010236>.
- Blair CD, Olson KE. 2015. The role of RNA interference (RNAi) in arbovirus-vector interactions. *Viruses* 7:820–843. <https://doi.org/10.3390/v7020820>.
- Johnson KN. 2015. The impact of *Wolbachia* on virus infection in mosquitoes. *Viruses* 7:5705–5717. <https://doi.org/10.3390/v7112903>.
- Alphey L. 2014. Genetic control of mosquitoes. *Annu Rev Entomol* 59:205–224. <https://doi.org/10.1146/annurev-ento-011613-162002>.
- Lindsey ARI, Bhattacharya T, Newton ILG, Hardy RW. 2018. Conflict in the intracellular lives of endosymbionts and viruses: a mechanistic look at *Wolbachia*-mediated pathogen-blocking. *Viruses* 10:141. <https://doi.org/10.3390/v10040141>.
- Terradas G, McGraw EA. 2017. *Wolbachia*-mediated virus blocking in the mosquito vector *Aedes aegypti*. *Curr Opin Insect Sci* 22:37–44. <https://doi.org/10.1016/j.cois.2017.05.005>.
- Jiggins FM. 2017. The spread of *Wolbachia* through mosquito populations. *PLoS Biol* 15:e2002780. <https://doi.org/10.1371/journal.pbio.2002780>.
- Macias VM, Ohm JR, Rasgon JL. 2017. Gene drive for mosquito control: where did it come from and where are we headed? *Int J Environ Res Public Health* 14:1006. <https://doi.org/10.3390/ijerph14091006>.
- Adelman ZN, Tu Z. 2016. Control of mosquito-borne infectious diseases: sex and gene drive. *Trends Parasitol* 32:219–229. <https://doi.org/10.1016/j.pt.2015.12.003>.
- Olson KE, Blair CD. 2015. Arbovirus-mosquito interactions: RNAi pathway. *Curr Opin Virol* 15:119–126. <https://doi.org/10.1016/j.coviro.2015.10.001>.
- Donald CL, Kohl A, Schnettler E. 2012. New insights into control of arbovirus replication and spread by insect RNA interference pathways. *Insects* 3:511–531. <https://doi.org/10.3390/insects3020511>.
- Bronkhorst AW, van Rij RP. 2014. The long and short of antiviral defense: small RNA-based immunity in insects. *Curr Opin Virol* 7:19–28. <https://doi.org/10.1016/j.coviro.2014.03.010>.
- Samuel GH, Adelman ZN, Myles KM. 2018. Antiviral immunity and virus-mediated antagonism in disease vector mosquitoes. *Trends Microbiol* 26:447–461. <https://doi.org/10.1016/j.tim.2017.12.005>.
- Keene KM, Foy BD, Sanchez-Vargas I, Beaty BJ, Blair CD, Olson KE. 2004. RNA interference acts as a natural antiviral response to O'nyong-nyong virus (Alphavirus; Togaviridae) infection of *Anopheles gambiae*. *Proc Natl Acad Sci U S A* 101:17240–17245. <https://doi.org/10.1073/pnas.0406983101>.
- Myles KM, Wiley MR, Morazzani EM, Adelman ZN. 2008. Alphavirus-derived small RNAs modulate pathogenesis in disease vector mosquitoes. *Proc Natl Acad Sci U S A* 105:19938–19943. <https://doi.org/10.1073/pnas.0803408105>.
- Schnettler E, Donald CL, Human S, Watson M, Siu RW, McFarlane M, Fazakerley JK, Kohl A, Fragkoudis R. 2013. Knockdown of piRNA pathway proteins results in enhanced Semliki Forest virus production in mosquito cells. *J Gen Virol* 94:1680–1689. <https://doi.org/10.1099/vir.0.053850-0>.
- McFarlane M, Arias-Goeta C, Martin E, O'Hara Z, Lulla A, Mousson L, Rainey SM, Misbah S, Schnettler E, Donald CL, Merits A, Kohl A, Failloux A-B. 2014. Characterization of *Aedes aegypti* innate-immune pathways that limit chikungunya virus replication. *PLoS Negl Trop Dis* 8:e2994. <https://doi.org/10.1371/journal.pntd.0002994>.
- Campbell CL, Keene KM, Brackney DE, Olson KE, Blair CD, Wilusz J, Foy BD. 2008. *Aedes aegypti* uses RNA interference in defense against Sindbis virus infection. *BMC Microbiol* 8:47. <https://doi.org/10.1186/1471-2180-8-47>.
- Varjak M, Dietrich I, Sreenu VB, Till BE, Merits A, Kohl A, Schnettler E. 2018. Spindle-E acts antivirally against alphaviruses in mosquito cells. *Viruses* 10:88. <https://doi.org/10.3390/v10020088>.
- Morazzani EM, Wiley MR, Murreddu MG, Adelman ZN, Myles KM. 2012. Production of virus-derived ping-pong-dependent piRNA-like small RNAs in the mosquito soma. *PLoS Pathog* 8:e1002470. <https://doi.org/10.1371/journal.ppat.1002470>.
- Carissimo G, Pondeville E, McFarlane M, Dietrich I, Mitri C, Bischoff E, Antoniewski C, Bourgouin C, Failloux AB, Kohl A, Vernick KD. 2015. Antiviral immunity of *Anopheles gambiae* is highly compartmentalized, with distinct roles for RNA interference and gut microbiota. *Proc Natl Acad Sci U S A* 112:E176–E185. <https://doi.org/10.1073/pnas.1412984112>.
- Waldock J, Olson KE, Christophides GK. 2012. *Anopheles gambiae* antiviral immune response to systemic O'nyong-nyong infection. *PLoS Negl Trop Dis* 6:e1565. <https://doi.org/10.1371/journal.pntd.0001565>.
- Varjak M, Maringer K, Watson M, Sreenu VB, Fredericks AC, Pondeville E, Donald CL, Sterk J, Kean J, Vazeille M, Failloux AB, Kohl A, Schnettler E. 2017. *Aedes aegypti* Piwi4 is a noncanonical PIWI protein involved in antiviral responses. *mSphere* 2:e00144-17. <https://doi.org/10.1128/mSphere.00144-17>.
- Sánchez-Vargas I, Scott JC, Poole-Smith BK, Franz AW, Barbosa-Solomieu V, Wilusz J, Olson KE, Blair CD. 2009. Dengue virus type 2 infections of *Aedes aegypti* are modulated by the mosquito's RNA interference pathway. *PLoS Pathog* 5:e1000299. <https://doi.org/10.1371/journal.ppat.1000299>.
- Samuel GH, Wiley MR, Badawi A, Adelman ZN, Myles KM. 2016. Yellow fever virus capsid protein is a potent suppressor of RNA silencing that binds double-stranded RNA. *Proc Natl Acad Sci U S A* 113:13863–13868. <https://doi.org/10.1073/pnas.1600544113>.
- Scott JC, Brackney DE, Campbell CL, Bondu-Hawkins V, Hjelle B, Ebel GD, Olson KE, Blair CD. 2010. Comparison of dengue virus type 2-specific small RNAs from RNA interference-competent and -incompetent mosquito cells. *PLoS Negl Trop Dis* 4:e848. <https://doi.org/10.1371/journal.pntd.0000848>.
- Franz AW, Sanchez-Vargas I, Adelman ZN, Blair CD, Beaty BJ, James AA, Olson KE. 2006. Engineering RNA interference-based resistance to dengue virus type 2 in genetically modified *Aedes aegypti*. *Proc Natl Acad Sci U S A* 103:4198–4203. <https://doi.org/10.1073/pnas.0600479103>.
- Varjak M, Donald CL, Mottram TJ, Sreenu VB, Merits A, Maringer K, Schnettler E, Kohl A. 2017. Characterization of the Zika virus induced small RNA response in *Aedes aegypti* cells. *PLoS Negl Trop Dis* 11:e0006010. <https://doi.org/10.1371/journal.pntd.0006010>.
- Dietrich I, Shi X, McFarlane M, Watson M, Blomstrom AL, Skelton JK, Kohl A, Elliott RM, Schnettler E. 2017. The antiviral RNAi response in vector and non-vector cells against orthobunyaviruses. *PLoS Negl Trop Dis* 11:e0005272. <https://doi.org/10.1371/journal.pntd.0005272>.
- Dietrich I, Jansen S, Fall G, Lorenzen S, Rudolf M, Huber K, Heitmann A, Schicht S, Ndiaye EH, Watson M, Castelli I, Brennan B, Elliott RM, Diallo M, Sall AA, Failloux AB, Schnettler E, Kohl A, Becker SC. 2017. RNA interfer-

- ence restricts Rift Valley fever virus in multiple insect systems. *mSphere* 2:e00090-17. <https://doi.org/10.1128/mSphere.00090-17>.
37. Léger P, Lara E, Jagla B, Sismeiro O, Mansuroglu Z, Coppee JY, Bonnefoy E, Bouloy M. 2013. Dicer-2- and Piwi-mediated RNA interference in Rift Valley fever virus-infected mosquito cells. *J Virol* 87:1631–1648. <https://doi.org/10.1128/JVI.02795-12>.
  38. Yasunaga A, Hanna SL, Li J, Cho H, Rose PP, Spiridigliozzi A, Gold B, Diamond MS, Cherry S. 2014. Genome-wide RNAi screen identifies broadly-acting host factors that inhibit arbovirus infection. *PLoS Pathog* 10:e1003914. <https://doi.org/10.1371/journal.ppat.1003914>.
  39. Castillo JC, Robertson AE, Strand MR. 2006. Characterization of hemocytes from the mosquitoes *Anopheles gambiae* and *Aedes aegypti*. *Insect Biochem Mol Biol* 36:891–903. <https://doi.org/10.1016/j.ibmb.2006.08.010>.
  40. Mutso M, Saul S, Rausalu K, Susova O, Zusinaite E, Mahalingam S, Merits A. 2017. Reverse genetic system, genetically stable reporter viruses and packaged subgenomic replicon based on a Brazilian Zika virus isolate. *J Gen Virol* 98:2712–2724. <https://doi.org/10.1099/jgv.0.000938>.
  41. Göertz GP, Vogels CBF, Geertsema C, Koenraad CJM, Pijlman GP. 2017. Mosquito co-infection with Zika and chikungunya virus allows simultaneous transmission without affecting vector competence of *Aedes aegypti*. *PLoS Negl Trop Dis* 11:e0005654. <https://doi.org/10.1371/journal.pntd.0005654>.
  42. Zhou R, Hotta I, Denli AM, Hong P, Perrimon N, Hannon GJ. 2008. Comparative analysis of Argonaute-dependent small RNA pathways in *Drosophila*. *Mol Cell* 32:592–599. <https://doi.org/10.1016/j.molcel.2008.10.018>.
  43. Jha S, Dutta A. 2009. RVB1/RVB2: running rings around molecular biology. *Mol Cell* 34:521–533. <https://doi.org/10.1016/j.molcel.2009.05.016>.
  44. Gupta A, Jha S, Engel DA, Ornelles DA, Dutta A. 2013. Tip60 degradation by adenovirus relieves transcriptional repression of viral transcriptional activator E1A. *Oncogene* 32:5017–5025. <https://doi.org/10.1038/ncr.2012.534>.
  45. Smith JA, Haberstroh FS, White EA, Livingston DM, DeCaprio JA, Howley PM. 2014. SMCX and components of the TIP60 complex contribute to E2 regulation of the HPV E6/E7 promoter. *Virology* 468–470:311–321. <https://doi.org/10.1016/j.virol.2014.08.022>.
  46. Hong S, Dutta A, Laimins LA. 2015. The acetyltransferase Tip60 is a critical regulator of the differentiation-dependent amplification of human papillomaviruses. *J Virol* 89:4668–4675. <https://doi.org/10.1128/JVI.03455-14>.
  47. Col E, Caron C, Chable-Bessia C, Legube G, Gazzeri S, Komatsu Y, Yoshida M, Benkirane M, Trouche D, Khochbin S. 2005. HIV-1 Tat targets Tip60 to impair the apoptotic cell response to genotoxic stresses. *EMBO J* 24:2634–2645. <https://doi.org/10.1038/sj.emboj.7600734>.
  48. Zhang SM, Song M, Yang TY, Fan R, Liu XD, Zhou PK. 2012. HIV-1 Tat impairs cell cycle control by targeting the Tip60, Plk1 and cyclin B1 ternary complex. *Cell Cycle* 11:1217–1234. <https://doi.org/10.4161/cc.11.6.19664>.
  49. Li R, Zhu J, Xie Z, Liao G, Liu J, Chen MR, Hu S, Woodard C, Lin J, Taverna SD, Desai P, Ambinder RF, Hayward GS, Qian J, Zhu H, Hayward SD. 2011. Conserved herpesvirus kinases target the DNA damage response pathway and TIP60 histone acetyltransferase to promote virus replication. *Cell Host Microbe* 10:390–400. <https://doi.org/10.1016/j.chom.2011.08.013>.
  50. Foley E, O'Farrell PH. 2003. Nitric oxide contributes to induction of innate immune responses to gram-negative bacteria in *Drosophila*. *Genes Dev* 17:115–125. <https://doi.org/10.1101/gad.1018503>.
  51. Braun A, Lemaitre B, Lanot R, Zachary D, Meister M. 1997. *Drosophila* immunity: analysis of larval hemocytes by P-element-mediated enhancer trap. *Genetics* 147:623–634.
  52. Ellis K, Friedman C, Yedvobnick B. 2015. *Drosophila* domino exhibits genetic interactions with a wide spectrum of chromatin protein-encoding loci. *PLoS One* 10:e0142635. <https://doi.org/10.1371/journal.pone.0142635>.
  53. Kwon MH, Callaway H, Zhong J, Yedvobnick B. 2013. A targeted genetic modifier screen links the SWI2/SNF2 protein domino to growth and autophagy genes in *Drosophila melanogaster*. *G3 (Bethesda)* 3:815–825. <https://doi.org/10.1534/g3.112.005496>.
  54. Ellis K, Wardwell-Ozgo J, Moberg KH, Yedvobnick B. 2018. The domino SWI2/SNF2 gene product represses cell death in *Drosophila melanogaster*. *G3 (Bethesda)* 8:2355–2360. <https://doi.org/10.1534/g3.118.200228>.
  55. Kusch T, Florens L, Macdonald WH, Swanson SK, Glaser RL, Yates JR, III, Abmayr SM, Washburn MP, Workman JL. 2004. Acetylation by Tip60 is required for selective histone variant exchange at DNA lesions. *Science* 306:2084–2087. <https://doi.org/10.1126/science.1103455>.
  56. Ruhf ML, Braun A, Papoulas O, Tamkun JW, Randsholt N, Meister M. 2001. The domino gene of *Drosophila* encodes novel members of the SWI2/SNF2 family of DNA-dependent ATPases, which contribute to the silencing of homeotic genes. *Development* 128:1429–1441.
  57. Subramanian V, Fields PA, Boyer LA. 2015. H2A.Z: a molecular rheostat for transcriptional control. *F1000Prime Rep* 7:01. <https://doi.org/10.12703/P7-01>.
  58. Harsh S, Ozakman Y, Kitchen SM, Paquin-Proulx D, Nixon DF, Eleftherianos I. 2018. Dicer-2 regulates resistance and maintains homeostasis against Zika virus infection in *Drosophila*. *J Immunol* 201:3058–3072. <https://doi.org/10.4049/jimmunol.1800597>.
  59. Liu Y, Gordesky-Gold B, Leney-Greene M, Weinbrein NL, Tudor M, Cherry S. 2018. Inflammation-induced, STING-dependent autophagy restricts Zika virus infection in the *Drosophila* brain. *Cell Host Microbe* 24:57–68.e3. <https://doi.org/10.1016/j.chom.2018.05.022>.
  60. Börner K, Becker PB. 2016. Splice variants of the SWR1-type nucleosome remodeling factor Domino have distinct functions during *Drosophila melanogaster* oogenesis. *Development* 143:3154–3167. <https://doi.org/10.1242/dev.139634>.
  61. Yan D, Neumuller RA, Buckner M, Ayers K, Li H, Hu Y, Yang-Zhou D, Pan L, Wang X, Kelley C, Vinayagam A, Binari R, Randklev S, Perkins LA, Xie T, Cooley L, Perrimon N. 2014. A regulatory network of *Drosophila* germline stem cell self-renewal. *Dev Cell* 28:459–473. <https://doi.org/10.1016/j.devcel.2014.01.020>.
  62. Xi R, Xie T. 2005. Stem cell self-renewal controlled by chromatin remodeling factors. *Science* 310:1487–1489. <https://doi.org/10.1126/science.1120140>.
  63. Eissenberg JC, Wong M, Chrvia JC. 2005. Human SRCAP and *Drosophila melanogaster* DOM are homologs that function in the notch signaling pathway. *Mol Cell Biol* 25:6559–6569. <https://doi.org/10.1128/MCB.25.15.6559-6569.2005>.
  64. Young AP, Schlisio S, Minamishima YA, Zhang Q, Li L, Grisanzio C, Signoretti S, Kaelin WG, Jr. 2008. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. *Nat Cell Biol* 10:361–369. <https://doi.org/10.1038/ncb1699>.
  65. Hsouna A, Nallamotheu G, Kose N, Guinea M, Dammai V, Hsu T. 2010. *Drosophila* von Hippel-Lindau tumor suppressor gene function in epithelial tubule morphogenesis. *Mol Cell Biol* 30:3779–3794. <https://doi.org/10.1128/MCB.01578-09>.
  66. Dong S, Kantor AM, Lin J, Passarelli AL, Clem RJ, Franz AW. 2016. Infection pattern and transmission potential of chikungunya virus in two New World laboratory-adapted *Aedes aegypti* strains. *Sci Rep* 6:24729. <https://doi.org/10.1038/srep24729>.
  67. Nainu F, Tanaka Y, Shiratsuchi A, Nakanishi Y. 2015. Protection of insects against viral infection by apoptosis-dependent phagocytosis. *J Immunol* 195:5696–5706. <https://doi.org/10.4049/jimmunol.1500613>.
  68. Lamiable O, Arnold J, de Faria I, Olmo RP, Bergami F, Meignin C, Hoffmann JA, Marques JT, Imler JL. 2016. Analysis of the contribution of hemocytes and autophagy to *Drosophila* antiviral immunity. *J Virol* 90:5415–5426. <https://doi.org/10.1128/JVI.00238-16>.
  69. Tassetto M, Kunitomi M, Andino R. 2017. Circulating immune cells mediate a systemic RNAi-based adaptive antiviral response in *Drosophila*. *Cell* 169:314–325.e13. <https://doi.org/10.1016/j.cell.2017.03.033>.
  70. Parikh GR, Oliver JD, Bartholomay LC. 2009. A haemocyte tropism for an arbovirus. *J Gen Virol* 90:292–296. <https://doi.org/10.1099/vir.0.005116-0>.
  71. Hilton L, Moganeradj K, Zhang G, Chen YH, Randall RE, McCauley JW, Goodbourn S. 2006. The NPro product of bovine viral diarrhoea virus inhibits DNA binding by interferon regulatory factor 3 and targets it for proteasomal degradation. *J Virol* 80:11723–11732. <https://doi.org/10.1128/JVI.01145-06>.
  72. Rodriguez-Andres J, Rani S, Varjak M, Chase-Topping ME, Beck MH, Ferguson MC, Schnettler E, Fragkoudis R, Barry G, Merits A, Fazakerley JK, Strand MR, Kohl A. 2012. Phenoloxidase activity acts as a mosquito innate immune response against infection with Semliki Forest virus. *PLoS Pathog* 8:e1002977. <https://doi.org/10.1371/journal.ppat.1002977>.
  73. Ulper L, Sarand I, Rausalu K, Merits A. 2008. Construction, properties, and potential application of infectious plasmids containing Semliki Forest virus full-length cDNA with an inserted intron. *J Virol Methods* 148:265–270. <https://doi.org/10.1016/j.jviromet.2007.10.007>.
  74. Ongus JR, Roode EC, Pleij CW, Vlask JM, van Oers MM. 2006. The 5'

- non-translated region of Varroa destructor virus 1 (genus *Flavirus*): structure prediction and IRES activity in *Lymantria dispar* cells. *J Gen Virol* 87:3397–3407. <https://doi.org/10.1099/vir.0.82122-0>.
75. Schnettler E, Sterken MG, Leung JY, Metz SW, Geertsema C, Goldbach RW, Vlak JM, Kohl A, Khromykh AA, Pijlman GP. 2012. Noncoding flavivirus RNA displays RNA interference suppressor activity in insect and mammalian cells. *J Virol* 86:13486–13500. <https://doi.org/10.1128/JVI.01104-12>.
76. Anderson MA, Gross TL, Myles KM, Adelman ZN. 2010. Validation of novel promoter sequences derived from two endogenous ubiquitin genes in transgenic *Aedes aegypti*. *Insect Mol Biol* 19:441–449. <https://doi.org/10.1111/j.1365-2583.2010.01005.x>.
77. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta CT}$  method. *Methods* 25:402–408. <https://doi.org/10.1006/meth.2001.1262>.
78. Taylor SC, Nadeau K, Abbasi M, Lachance C, Nguyen M, Fenrich J. 2019. The ultimate qPCR experiment: producing publication quality, reproducible data the first time. *Trends Biotechnol* 37:761–774. <https://doi.org/10.1016/j.tibtech.2018.12.002>.